by Maria Zannes | Jun 24, 2025 | Press Releases
Company research targets topical application for treatment of skin cancers SAN ANTONIO, TX — June 24, 2025 — bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company advancing early-stage diagnostics and targeted therapeutics for cancer, today...
by Maria Zannes | Jun 11, 2025 | Press Releases
SAN ANTONIO, TX – June 11, 2025 – bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage lung cancer and other diseases of the lung, today announced that its...
by Maria Zannes | Jun 3, 2025 | Press Releases
SAN ANTONIO, TX – (June 3, 2025) – bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company advancing noninvasive diagnostics and targeted therapeutics for cancer, today announced publication of “The Drive for Early Detection,” a case study...
by Maria Zannes | May 28, 2025 | Press Releases
Simultaneous siRNA Knockdown of Specific Cell Receptors Shown to Selectively Kill Cancer Company Research Targets Topical Application for Treatment of Skin Cancers SAN ANTONIO, TX — May 28, 2025 — bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology...
by Maria Zannes | May 20, 2025 | Press Releases
SAN ANTONIO, TX — May 20, 2025 — bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage cancer, today announced the appointment of Gordon Downie, MD, PhD, as...
